...
首页> 外文期刊>Nuclear Medicine Communications >Tc-99m-labeled single-domain antibody EG2 in targeting epidermal growth factor receptor: an in-vitro and mouse model in-vivo study
【24h】

Tc-99m-labeled single-domain antibody EG2 in targeting epidermal growth factor receptor: an in-vitro and mouse model in-vivo study

机译:靶向表皮生长因子受体的Tc-99m标记单域抗体EG2:体内和小鼠体内模型研究

获取原文
获取原文并翻译 | 示例
           

摘要

ObjectiveThe aim of this study was to explore the targeting ability and metabolic characteristics of the technetium-99m-labeled single-domain antibody (Tc-99m-sdAb) EG2 targeting epidermal growth factor receptor (EGFR) through an in-vitro and in-vivo study.Materials and methodsThe sdAb EG2 was radiolabeled with Tc-99m using a tricarbonyl kit. The EGFR expression level of A431 and OCM-1 cells was confirmed using immunofluorescence staining. Cell binding, blocking, uptake, and efflux studies were performed to investigate the binding specificity of Tc-99m-sdAb EG2 in vitro. Single-photon emission computed tomography imaging and biodistribution studies were used to explore the targeting abilities and metabolic characteristics of Tc-99m-sdAb EG2 in vivo.Results(99m)Tc-sdAb EG2 was successfully prepared with labeling yields of 60-71% and specific activity of 1.830.29GBq/mg (n=3). Immunofluorescence staining revealed high and low EGFR expression on the surface of A431 and OCM-1 cells, respectively. The binding affinity of Tc-99m-sdAb EG2 to A431 cells was 43.53 +/- 1.89nmol/l. Tc-99m-sdAb EG2 uptake in A431 cells in vitro could be blocked by approximate to 19, 40, and 66% in the presence of excess unlabeled sdAb EG2 at 100, 500, and 1000nmol/l, respectively. Single-photon emission computed imaging indicated that A431 tumor images could be clearly displayed at early scan time points after Tc-99m-sdAb EG2 injection, even as early as 1h. Biodistribution study showed that the A431 tumor uptake of Tc-99m-sdAb EG2 was blocked by about 51% at 3h after coinjecting excess of sdAb EG2. However, there were almost no OCM-1 tumor images at the corresponding scan time points and the OCM-1 tumor uptake was only 0.40 +/- 0.13% injected dose per gram of tissue (n=5) at 3h.ConclusionThis study demonstrated that sdAb EG2 can effectively target EGFR in vitro and in vivo in tumors, suggesting that it could be used as a molecular probe for EGFR detection.
机译:目的本研究的目的是通过体内和体外探索targeting 99m标记的单域抗体(Tc-99m-sdAb)EG2靶向表皮生长因子受体(EGFR)的靶向能力和代谢特征材料和方法使用三羰基试剂盒将Td-99m放射性标记sdAb EG2。使用免疫荧光染色确认了A431和OCM-1细胞的EGFR表达水平。进行了细胞结合,阻断,摄取和流出研究,以研究Tc-99m-sdAb EG2在体外的结合特异性。利用单光子发射计算机断层显像和生物分布研究来探索Tc-99m-sdAb EG2在体内的靶向能力和代谢特性。结果成功制备了(99m)Tc-sdAb EG2,标记产率为60-71%,比活为1.830.29GBq / mg(n = 3)。免疫荧光染色分别在A431和OCM-1细胞表面显示高和低的EGFR表达。 Tc-99m-sdAb EG2与A431细胞的结合亲和力为43.53 +/- 1.89nmol / l。在过量的未标记sdAb EG2浓度分别为100、500和1000nmol / l的情况下,体外A431细胞中Tc-99m-sdAb EG2的吸收可被阻止约19%,40%和66%。单光子发射计算的成像表明,在Tc-99m-sdAb EG2注射后,甚至早在1小时后,A431肿瘤图像都可以在早期扫描时间点清晰显示。生物分布研究表明,在共注射过量的sdAb EG2后3小时,Tc-99m-sdAb EG2的A431肿瘤摄取被阻止了约51%。但是,在相应的扫描时间点几乎没有OCM-1肿瘤图像,并且在3h时,每克组织(n = 5)的OCM-1肿瘤摄取仅为0.40 +/- 0.13%注射剂量。 sdAb EG2可以在肿瘤体内和体外有效靶向EGFR,表明它可以用作EGFR检测的分子探针。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号